Cimerli™ (ranibizumab-eqrn) was FDA approved on August 2, 2022 as interchangeable with Lucentis ® (ranibizumab). Cimerli is the third interchangeable biosimilar approved in the US, following Semglee ® ...

Next, AbbVie argues that biological products are fundamentally different from small molecule drugs because they are more likely to be immunogenic and biosimilars cannot be shown to be the same as ...

The designation means that pharmacists can switch patients to the less-expensive version of insulin without seeking approval from the clinician. An interchangeable designation means that the product, ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Abrilada as the second interchangeable biosimilar to adalimumab, according to a press ...

Biologics have revolutionized the management of immune-mediated inflammatory diseases (IMIDs). Biosimilars are biologics that exhibit no significant differences in safety or efficacy compared with ...

The Food and Drug Administration’s decision on Wednesday to approve a long-acting insulin called Semglee (insulin glargine-yfgn) as the first interchangeable biologic licensed for the U.S. market ...

Please provide your email address to receive an email when new articles are posted on . Express Scripts will prefer Viatris’ insulin glargine-yfgn injection, the first FDA-approved interchangeable ...

President Joe Biden’s budget proposal for fiscal 2025 includes a proposal that would allow pharmacy substitution of biosimilar drugs for the reference product, even if they are not designated as ...